Inventiva SA
IVAHealthcare|Biotechnology|France
$4.29
-0.21 (-4.66%)
Upcoming Data Readouts (2)
Sep 2027
Est. completion
P3NASH - Nonalcoholic Steatohepatitis
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728n=1,000
Mar 2031
Est. completion